Share on StockTwits

Alder Biopharmaceuticals (NASDAQ:ALDR) posted its quarterly earnings results on Wednesday. The company reported ($5.38) earnings per share (EPS) for the quarter, Analyst Ratings.Net reports. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $4.60 million.

A number of research firms have recently commented on ALDR. Analysts at Bernstein initiated coverage on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 11th. They set an “outperform” rating and a $30.00 price target on the stock. On a related note, analysts at Sanford C. Bernstein initiated coverage on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 11th. They set an “outperform” rating on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of Alder Biopharmaceuticals in a research note on Monday, June 2nd. They set an “outperform” rating and a $20.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $25.33.

Alder Biopharmaceuticals (NASDAQ:ALDR) traded down 4.10% on Wednesday, hitting $17.55. The stock had a trading volume of 339,161 shares. Alder Biopharmaceuticals has a 1-year low of $9.50 and a 1-year high of $22.95. The stock has a 50-day moving average of $12.72 and a 200-day moving average of $12.72. The company’s market cap is $524.8 million.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.